Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzenesulfonamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 14/20 | 0.76 |
| ▸ | CA2 | P00918 | 14/20 | 0.76 |
| ▸ | CA9 | Q16790 | 13/20 | 0.76 |
| ▸ | CA12 | O43570 | 12/20 | 0.76 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.76 |
| ▸ | CA3 | P07451 | 2/20 | 0.76 |
| ▸ | CA6 | P23280 | 2/20 | 0.76 |
| ▸ | CA5A | P35218 | 2/20 | 0.76 |
| ▸ | CA7 | P43166 | 2/20 | 0.76 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.76 |
| ▸ | CA4 | P22748 | 2/20 | 0.76 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.76 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzenesulfonamide SCHEMBL28658299 | 0.93 | CA2 (0.73) | CA1CA2CA9CA12CA14 | |
| Benzenesulfonamide SCHEMBL9491339 | 0.90 | CA2 (0.84) | CA1CA2CA9CA12CA14 | |
| Benzenesulfonamide SCHEMBL27607325 | 0.88 | CA1 (0.59) | CA1CA2CA9CA12CA14 | |
| Benzenesulfonamide SCHEMBL3971272 | 0.88 | CA2 (0.80) | CA1CA2CA9CA12CA14 | |
| Benzenesulfonamide SCHEMBL19348104 | 0.88 | CA2 (0.80) | CA1CA2CA9CA12CA14 | |
| Benzenesulfonamide SCHEMBL27896159 | 0.88 | CA2 (0.80) | CA1CA2CA9CA12CA14 | |
| Benzenesulfonamide SCHEMBL28194516 | 0.87 | CA2 (0.89) | CA1CA2CA9CA12CA14 | |
| Benzenesulfonamide SCHEMBL729 | 0.87 | CA2 (1.00) | CA1CA2CA9CA12CA14 | |
| Benzenesulfonamide SCHEMBL29825137 | 0.87 | CA2 (1.00) | CA1CA2CA9CA12CA14 | |
| Benzenesulfonamide SCHEMBL6868390 | 0.87 | CA2 (1.00) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1192021-C | 3-azabicyclo [3.1.0] hexane derivatives as opioid receptor ligands | PFIZER LTD (US) | 2005-03-09 | — | — | CN | claimed |
| CN-103288793-A | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LTD | 2013-09-11 | — | — | CN | disclosed |
| CN-103003240-A | Substituted biaryl benzenesulfonamide compound and use | SINOCHEM CORP | 2013-03-27 | — | — | CN | disclosed |
| CN-1585633-B | Phenylethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LTD | 2010-10-27 | — | — | CN | disclosed |
| CN-101701006-A | Phenethanolamine derivatives for treatment of respiratory diseases | GLAXO GROUP LTD | 2010-05-05 | — | — | CN | disclosed |
| US-20080275073-A1 | CRYSTALLINE FORMS AND POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS PHARMACEUTICALLY ACCEPTABLE SALTS | WYETH (US) | 2008-11-06 | — | — | US | disclosed |
| CN-1302007-C | 17 beta-thiocarboxylic ester derivatives of androstanes with a cyclic ester group in the 17 alpha position having anti-inflammatory properties | GLAXO GROUP LTD (GB) | 2007-02-28 | — | — | CN | disclosed |
| CN-1266126-C | Phenylethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LTD (GB) | 2006-07-26 | — | — | CN | disclosed |
| CN-1192021-C | 3-azabicyclo [3.1.0] hexane derivatives as opioid receptor ligands | PFIZER LTD (US) | 2005-03-09 | — | — | CN | disclosed |
| CN-1585633-A | Phenylethanolamine derivatives for the treatment of respiratory diseases | GLAXO GROUP LTD (GB) | 2005-02-23 | — | — | CN | disclosed |
| CN-1501911-A | Phenethanolamine derivatives for treatment of respiratory diseases | — | 2004-06-02 | — | — | CN | disclosed |
| EP-1360174-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002066422-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |
| CN-1202828-A | Substituted pyrzolyl benzenesulfonanides for use in veterinary | SEARLE & CO (US) | 1998-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275073-A1 | CRYSTALLINE FORMS AND POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS PHARMACEUTICALLY ACCEPTABLE SALTS | ABCG2, CYP3A43, CYP2D6 | CA1 3793/4885CA2 2148/4885CA9 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.